XML 49 R34.htm IDEA: XBRL DOCUMENT v3.19.1
Interim Financial Results (Unaudited)
 12 Months Ended
Mar. 02, 2019
Interim Financial Results (Unaudited)  
Interim Financial Results (Unaudited)

25. Interim Financial Results (Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fiscal Year 2019

 

 

First

 

Second

 

Third

 

Fourth

 

 

 

 

    

Quarter(a)

    

Quarter(a)

    

Quarter

    

Quarter

    

Year

Revenues

    

$

5,388,490

 

$

5,421,362

 

$

5,450,060

 

$

5,379,645

 

$

21,639,557

Cost of revenues

 

 

4,219,741

 

 

4,260,211

 

 

4,267,972

 

 

4,215,281

 

 

16,963,205

Selling, general and administrative expenses

 

 

1,152,627

 

 

1,153,991

 

 

1,142,555

 

 

1,143,202

 

 

4,592,375

Lease termination and impairment charges

 

 

9,859

 

 

39,609

 

 

2,628

 

 

55,898

 

 

107,994

Goodwill and intangible asset impairment charges

 

 

—

 

 

375,190

 

 

 —

 

 

 —

 

 

375,190

Interest expense

 

 

62,792

 

 

56,233

 

 

56,008

 

 

52,695

 

 

227,728

Loss on debt retirements, net

 

 

 554

 

 

 —

 

 

 —

 

 

 —

 

 

 554

Gain on sale of assets, net

 

 

(5,859)

 

 

(4,965)

 

 

(382)

 

 

(26,806)

 

 

(38,012)

 

 

 

5,439,714

 

 

5,880,269

 

 

5,468,781

 

 

5,440,270

 

 

22,229,034

Loss from continuing operations before income taxes

 

 

(51,224)

 

 

(458,907)

 

 

(18,721)

 

 

(60,625)

 

 

(589,477)

Income tax (benefit) expense

 

 

(9,497)

 

 

(106,559)

 

 

(1,471)

 

 

195,004

 

 

77,477

Loss from continuing operations

 

 

(41,727)

 

 

(352,348)

 

 

(17,250)

 

 

(255,629)

 

 

(666,954)

Net income (loss) from discontinued operations, net of tax

 

 

256,143

 

 

(6,792)

 

 

12,740

 

 

(17,350)

 

 

244,741

Net income (loss)

 

 

214,416

 

 

(359,140)

 

 

(4,510)

 

 

(272,979)

 

 

(422,213)

Basic and diluted income (loss) per share(a):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

(0.79)

 

$

(6.67)

 

$

(0.33)

 

$

(4.83)

 

$

(12.62)

Discontinued operations

 

$

4.86

 

$

(0.13)

 

$

0.24

 

$

(0.32)

 

$

4.63

Net basic and diluted income (loss) per share

 

$

4.07

 

$

(6.80)

 

$

(0.09)

 

$

(5.15)

 

$

(7.99)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fiscal Year 2018

 

 

First

 

Second

 

Third

 

Fourth

 

 

 

 

    

Quarter

    

Quarter

    

Quarter

    

Quarter

    

Year

Revenues

 

$

5,436,523

 

$

5,345,011

 

$

5,353,170

 

$

5,394,264

 

$

21,528,968

Cost of revenues

 

 

4,274,580

 

 

4,183,338

 

 

4,166,447

 

 

4,124,498

 

 

16,748,863

Selling, general and administrative expenses

 

 

1,160,940

 

 

1,141,844

 

 

1,166,514

 

 

1,181,964

 

 

4,651,262

Lease termination and impairment charges

 

 

4,038

 

 

3,113

 

 

3,939

 

 

47,675

 

 

58,765

Goodwill impairment

 

 

 —

 

 

 —

 

 

 —

 

 

261,727

 

 

261,727

Interest expense

 

 

51,000

 

 

50,857

 

 

50,308

 

 

50,603

 

 

202,768

Walgreens Boots Alliance merger termination fee

 

 

 —

 

 

(325,000)

 

 

 —

 

 

 —

 

 

(325,000)

Loss (gain) on sale of assets, net

 

 

(5,877)

 

 

(14,951)

 

 

205

 

 

(5,249)

 

 

(25,872)

 

 

 

5,484,681

 

 

5,039,201

 

 

5,387,413

 

 

5,661,218

 

 

21,572,513

(Loss) income from continuing operations before income taxes

 

 

(48,158)

 

 

305,810

 

 

(34,243)

 

 

(266,954)

 

 

(43,545)

Income tax (benefit) expense

 

 

(12,121)

 

 

117,450

 

 

(16,061)

 

 

216,719

 

 

305,987

Net (loss) income from continuing operations

 

 

(36,037)

 

 

188,360

 

 

(18,182)

 

 

(483,673)

 

 

(349,532)

Net (loss) income from discontinued operations, net of tax

 

 

(39,312)

 

 

(17,644)

 

 

99,213

 

 

1,250,745

 

 

1,293,002

Net (loss) income

 

$

(75,349)

 

$

170,716

 

$

81,031

 

$

767,072

 

$

943,470

Basic (loss) income per share(a):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

(0.69)

 

$

3.59

 

$

(0.35)

 

$

(9.18)

 

$

(6.66)

Discontinued operations

 

$

(0.75)

 

$

(0.33)

 

$

1.90

 

$

23.74

 

$

24.64

Net  basic (loss)  income per share

 

$

(1.44)

 

$

3.26

 

$

1.55

 

$

14.56

 

$

17.98

Diluted (loss) income per share(a):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

(0.69)

 

$

3.53

 

$

(0.35)

 

$

(9.18)

 

$

(6.66)

Discontinued operations

 

$

(0.75)

 

$

(0.33)

 

$

1.90

 

$

23.74

 

$

24.64

Net diluted (loss) income per share

 

$

(1.44)

 

$

3.20

 

$

1.55

 

$

14.56

 

$

17.98

(a)

Income per share amounts for each quarter may not necessarily total to the yearly income per share due to the weighting of shares outstanding on a quarterly and year-to-date basis.

During the fourth quarter of fiscal 2019, the Company recorded an income tax expense of $212,252 in connection with the revaluation of the Company’s deferred tax assets resulting from an increase in the valuation allowance as discussed in Note 7 and facilities impairment charges of $28,920. Also, during the fourth quarter of fiscal 2019, the Company recorded a LIFO charge of $4,043 due to higher inflation on pharmaceutical drugs as compared to a LIFO credit recognized at prior year end caused by deflation on pharmacy generics.

During the fourth quarter of fiscal 2018, the Company recorded an income tax expense of $324,765 in connection with the revaluation of the Company’s deferred tax assets as a result of the Tax Act as discussed in Note 7, a goodwill impairment charge of $261,727 ($191,000 net of the related income tax benefit), and facilities impairment charges of $36,927. Also, during the fourth quarter of fiscal 2018, the Company recorded a LIFO credit of $49,220 due to higher deflation on pharmacy generics as compared to a LIFO credit recognized at prior year end caused by lower deflation on pharmacy generics.